Search
SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)
go.drugbank.com/drugs/DB18705Approved[L48902,L48907] Bimervax was issued marketing authorization in the EU in March 2023 for use as a booster dose in patients who have previously received an mRNA COVID-19 vaccine.[L48907] … [L48902] It is intended to elicit protection against Omicron XBB.1.5, one of the dominant circulating SARS-CoV-2 subvariants in 2023.
Enalaprilat
go.drugbank.com/drugs/DB09477ApprovedInvestigationalUsed in the treatment of hypertension, enalapril is an ACE inhibitor that prevents Angiotensin Converting Enzyme (ACE) from transforming angiotensin I into angiotensin II. … Removal of the problematic thiol group from captopril resulted in enalaprilat, which was then modified further with an ester to create the orally available pro-drug enalapril.
Categories: Agents Acting on the Renin-Angiotensin SystemHydroxyprogesterone caproate
go.drugbank.com/drugs/DB06789ApprovedFood and Drug Administration (FDA) in 1956 and withdrawn from marketing in 1999.[L46118] The U.S. … In April 2023, the FDA withdrew its approval of Makena and its generics given an unfavorable risk-to-benefit assessment.[L46113]
Synonyms: 17alpha-Caproyloxypregn-4-ene-3,20-dioneIohexol
go.drugbank.com/drugs/DB01362ApprovedInvestigationalIohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.
Categories: Compounds used in a research, industrial, or household settingSynonyms: N,N'-Bis(2,3-dihydroxypropyl)-5-(N-(2,3-dihydroxypropyl)acetamido)-2,4,6-triiodoisophthalamideViloxazine
go.drugbank.com/drugs/DB09185ApprovedInvestigationalWithdrawn[L41685] For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant. … In the US, viloxazine was assigned an orphan drug designation in 1984 under the brand name CATATROL: while this product was intended to treat cataplexy and narcolepsy, the drug was never approved for these
Raloxifene
go.drugbank.com/drugs/DB00481ApprovedInvestigational[A4977] Available in many countries worldwide, raloxifene was initially approved by the FDA in December, 1997 under the market name Evista® for the management and prevention of osteoporosis in postmenopausal … women and reduction in risk for invasive breast cancer in postmenopausal women with osteoporosis or those who are at high risk for invasive breast cancer.
Iron Dextran
go.drugbank.com/drugs/DB00893ApprovedInvestigationalVet approvedIron Dextran is used for the treatment of patients with documented iron deficiency in which oral administration is unsatisfactory or impossible.
Categories: Compounds used in a research, industrial, or household settingIopromide
go.drugbank.com/drugs/DB09156Approved[A260751] Approved by the FDA in 1995 and Health Canada in 1994 under the brand name ULTRAVIST, iopromide is used in radiological diagnosis, including, but not limited to, intra-arterial digital subtraction … It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs
Categories: Compounds used in a research, industrial, or household settingSynonyms: N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(methoxyacetyl)amino]-N-methylisophthalamideMethylchloroisothiazolinone
go.drugbank.com/drugs/DB14197ApprovedMethylchloroisothiazolinone (MCI) is an isothiazolinone commonly used as a preservative with antibacterial and antifungal properties. … It is also a known dermatological sensitizer and allergen; some of its side effects include flaky or scaly skin, breakouts, redness or itchiness, and moderate to severe swelling in the eye area.
Categories: Compounds used in a research, industrial, or household settingSynonyms: 5-Chloro-N-methylisothiazolin-3-oneOlipudase alfa
go.drugbank.com/drugs/DB12835ApprovedInvestigational[A251590] Olipudase alfa gained its first global approval in Japan on March 28, 2022. … [A251590] It was later approved by the European Commission on June 28, 2022 [L42740] and by the FDA on August 31, 2022.[L43145]